Ad
related to: therapeutics
Search results
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time...
Motley Fool via Yahoo Finance· 51 minutes agoShares of Structure Therapeutics (NASDAQ: GPCR) shot up more than 50% during the first week of June....
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 1,133 Shares
ETF DAILY NEWS· 4 hours agoEnliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 1,133 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold ...
Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $64.86
ETF DAILY NEWS· 7 hours agoArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the ...
Enliven Therapeutics COO sells over $22k in company stock By Investing.com
Investing.com· 11 hours agoEnliven Therapeutics, Inc. (NASDAQ:ELVN) has reported a recent transaction involving its Chief...
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of “Hold” by Analysts
ETF DAILY NEWS· 8 hours agoFate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has earned a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat ...
Rapport Therapeutics director buys $9.5 million in company stock By Investing.com
Investing.com· 10 hours agoDirector of Rapport Therapeutics, Inc. (NASDAQ:RAPP), James Healy, has recently made a substantial...
With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional...
Simply Wall St. via Yahoo Finance· 16 hours agoKey Insights Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is...
StockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Sell
ETF DAILY NEWS· 4 days agoProQR Therapeutics (NASDAQ:PRQR – Get Free Report) was downgraded by investment analysts at...
GSK acquires Elsie to unlock oligonucleotide therapeutics
Pharmaceutical Technology via Yahoo Finance· 4 days agoGSK has acquired Elsie Biotechnologies for $50m to unlock the potential of oligonucleotide ...
Halozyme Therapeutics Scores RS Rating Jump To 91
Investor's Business Daily· 4 days agoOn Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. See if the biotech stock forms a new...
